Top News
Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
Managing Neutropenic Sepsis in Patients With Cancer
Genomic Characterization of Chemoresistant Metastatic Small Cell Lung Cancer
Promising Early Results for Tisotumab Vedotin in Advanced Cervical Cancer
Adjuvant Chemotherapy Not Associated With Improved Survival in Stage I Uterine Leiomyosarcoma
Early Evidence of Neratinib Benefit in HER2-Positive Metastatic Cervical Cancer
Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
Molecular Characterization of Pediatric Follicular Lymphoma
Vitiligo May Be Associated With Reduced Risk of Internal Cancer
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Genomic Profiling May Detect Lung Cancer Early
Researchers say they can distinguish between lesions that are benign and those that could become invasive — but the technology required is not yet used routinely. -
Multiple Myeloma and Infections: Characterizing the Risks
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged. -
Phytochemicals and Cancer
This fact sheet describes phytochemicals and the rationale behind their potential use as a chemopreventive. -
Time to Treatment Discontinuation Makes Headway as Real-World End Point
An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting. -
Cabozantinib a Viable Choice for Non-Clear Cell Renal Cell Carcinoma
There are no biomarkers that have been prospectively validated to help predict which patients with non-clear cell RCC might respond to cabozantinib.
More Features
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
The Downstream Effect of Misrepresented Clinical Trial Data
Data quality issues borne out in clinical trials don’t always reach peer reviewers, and as a result, may not reach prescribers, either.
NSAIDs in Head and Neck Cancer Bring New Meaning to Precision Medicine
Patients with PIK3CA-altered head and neck cancers lived longer if they took NSAIDs, suggesting old drugs may have new clinical uses.
Active Surveillance: Is it an Appropriate Approach for Thyroid Cancer?
In patients with thyroid cancer, active surveillance has been controversial because surgery is the standard of care.
Chemobrain: Experts Weigh in on Very Real — and Growing — Problem
Major advances in cancer treatment in recent decades have allowed patient survival rates to increase.
